Submissions for variant NM_000249.4(MLH1):c.350C>T (p.Thr117Met)

dbSNP: rs63750781

Total submissions: 26

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
International Society for Gastrointestinal Hereditary Tumours (InSiGHT)	RCV000075666	SCV000106668	pathogenic	Lynch syndrome	2013-09-05	reviewed by expert panel	research	Abrogated function, >2 MSI-H tumours, co-segregation with disease & MAF 0.00. Multifactorial likelihood analysis posterior probability >0.99
GeneDx	RCV000160518	SCV000211084	pathogenic	not provided	2021-10-21	criteria provided, single submitter	clinical testing	Published functional studies demonstrate a damaging effect: abrogated or significantly reduced MMR activity, no dominant mutator effect (Shimodaira 1998, Shcherbakova 1999, Trojan 2002, Plotz 2006, Vogelsang 2009, Hinrichsen 2013, Thompson 2014); Not observed at a significant frequency in large population cohorts (Lek 2016); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 22736432, 11429708, 23403630, 12377806, 22949379, 25420488, 25980754, 28874130, 10082584, 18547406, 23760103, 22949387, 25117503, 15340264, 19267393, 12200596, 12112654, 14564042, 12373605, 12919140, 11601928, 16395668, 19072991, 15996210, 18726168, 18772310, 21387278, 12555990, 18618713., 21642682, 16995940, 18561205, 17192056, 18383312, 11385712, 11139242, 16451135, 12362047, 16528606, 18566915, 17713103, 15713769, 20215533, 24362816, 9697702, 11781295, 12810663, 17135187, 17510385, 17594722, 19863800, 20864636, 20176959, 20020535, 22753075, 8574961, 27064304, 27601186, 27013479, 22322191, 28127413, 28449805, 28251689, 26681312, 28640387, 25248401, 29478780, 29752822, 28135145, 29505604, 8566964, 10732761, 16830052, 17026620, 9806477, 30521064, 29887214, 30720243, 30998989, 31054147, 31350202, 31491536, 31447099, 31948886, 32719484, 31332305, 33654310)
Invitae	RCV000524293	SCV000211908	pathogenic	Hereditary nonpolyposis colorectal neoplasms	2023-11-27	criteria provided, single submitter	clinical testing	This sequence change replaces threonine, which is neutral and polar, with methionine, which is neutral and non-polar, at codon 117 of the MLH1 protein (p.Thr117Met). This variant is present in population databases (rs63750781, gnomAD 0.003%). This missense change has been observed in individual(s) with colon cancer and Lynch syndrome (PMID: 12112654, 15713769, 18566915, 19698169, 20233461, 22322191). ClinVar contains an entry for this variant (Variation ID: 17094). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt MLH1 protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects MLH1 function (PMID: 9697702, 11429708, 11781295, 12810663, 17135187, 17510385, 23403630). This variant disrupts the p.Thr117 amino acid residue in MLH1. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 9697702, 11555625, 12810663). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.
University of Washington Department of Laboratory Medicine, University of Washington	RCV000075666	SCV000266078	pathogenic	Lynch syndrome	2015-11-20	criteria provided, single submitter	clinical testing
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine	RCV000075666	SCV000271399	pathogenic	Lynch syndrome	2016-03-23	criteria provided, single submitter	clinical testing	The p.Thr117Met variant in MLH1 has been reported in >50 individuals with MLH1-a ssociated tumors (Kurzawski 2002, Wei 2003, Liu 1996, Maliaka 1996, Yap 2008, Ca sey 2005; InSiGHT database: http://chromium.lovd.nl/LOVD2/colon_cancer/variants. php) and segregated with disease in at least 2 affected family members (Zavodna 2006). This variant was absent from large population studies. In vitro functiona l studies provide some evidence that the p.Thr117Met variant is deficient in mis match repair (Trojan 2002). Computational prediction tools and conservation anal ysis suggest that this variant may impact the protein, though this information a lone is not predictive enough to determine pathogenicity. Additionally, this var iant has been classified as pathogenic on Nov 26, 2014 by the ClinGen-approved I nSiGHT panel (ClinVar SCV000211908.2). In summary, this variant meets our criter ia to be classified as pathogenic for Lynch syndrome in an autosomal dominant ma nner. ACMG/AMP criteria applied: PS4, PM2, PS3, PP3 (Richards 2015).
Ambry Genetics	RCV000570680	SCV000669513	pathogenic	Hereditary cancer-predisposing syndrome	2022-01-21	criteria provided, single submitter	clinical testing	The p.T117M pathogenic mutation (also known as c.350C>T), located in coding exon 4 of the MLH1 gene, results from a C to T substitution at nucleotide position 350. The threonine at codon 117 is replaced by methionine, an amino acid with similar properties. This mutation has been reported in multiple hereditary non-polyposis colorectal cancer (HNPCC)/Lynch syndrome patients meeting Amsterdam diagnostic criteria; several whose tumors demonstrated high microsatellite instability and/or loss of MLH1 staining by immunohistochemistry (IHC) (Buerstedde JM et al. J. Med. Genet., 1995 Nov;32:909-12; Maliaka YK et al. Hum. Genet., 1996 Feb;97:251-5; Bennett G et al. Clin. Chem. Lab. Med.,1998 Aug;36:641-4; Kurzawski G et al. J Med Genet, 2002 Oct;39:E65; Wei SC et al. Clin Genet, 2003 Sep;64:243-51; Pigatto F et al. Hered Cancer Clin Pract, 2004 Nov;2:175-84; Christensen LL et al. BMC Med Genet, 2008 Jun;9:52; Ollila S et al. Int J Cancer, 2008 Aug;123:720-4; Nilbert M et al. Fam Cancer, 2009 Jun;8:75-83; Choi YH et al. Hered Cancer Clin Pract, 2009 Aug;7:14; Yap HL et al. Fam Cancer, 2009 Aug;8:85-94; Vogelsang M et al. BMC Cancer, 2009 Oct;9:382; Walsh MD et al. Mod Pathol, 2012 May;25:722-30; Toon CW et al. Am J Surg Pathol, 2013 Oct;37:1592-602; Rosty C et al. Fam Cancer, 2014 Dec;13:573-82; Shirts BH et al. Genet Med, 2016 10;18:974-81; Susswein LR et al. Genet Med, 2016 08;18:823-32; Sunga AY et al. Cancer Genet, 2017 04;212-213:1-7; Jiang W et al. Int J Cancer, 2019 05;144:2161-2168; Tian W et al. Int J Cancer, 2019 09;145:1290-1298; Ow SGW et al. Clin Colorectal Cancer, 2019 12;18:e324-e334; Yanus GA et al. Eur J Med Genet, 2020 Mar;63:103753; Talbot A et al. BMC Cancer, 2021 May;21:617; Frostberg E et al. Cancers (Basel), 2021 Oct;13). This mutation has also been reported in breast and prostate cancer cohorts (Walsh MD et al. Clin Cancer Res 2010 Apr;16(7):2214-24; Rosty C et al. Fam Cancer, 2014 Dec;13:573-82; Li JY et al. Int J Cancer, 2019 01;144:281-289; Wu Y et al. Eur Urol Oncol, 2020 04;3:224-230). Multiple functional studies have demonstrated that the T117M alteration has reduced protein expression, deficient MMR activity, inactivated hMLH1-induced dominant mutator effect, and impaired interaction with hPMS2 (Shimodaira H et al. Nat Genet, 1998 Aug;19:384-9; Jäger AC et al. Oncogene, 2001 Jun;20:3590-5; Trojan J et al. Gastroenterology, 2002 Jan;122:211-9; Brieger A et al. Gut, 2002 Nov;51:677-84; Takahashi M et al. Cancer Res, 2007 May;67:4595-604; Drost M et al. Hum Mutat, 2010 Mar;31:247-53; Hinrichsen I et al. Clin Cancer Res, 2013 May;19:2432-41). Two other alterations at the same codon, p.T117R and p.T117K, have been detected in multiple hereditary non-polyposis colorectal cancer (HNPCC)/Lynch syndrome patients meeting Amsterdam diagnostic criteria (Buerstedde JM et al. J. Med. Genet. 1995 Nov;32:909-12; Heinimann K et al Cancer. 1999 Jun 15;85(12):2512-8; Ellison AR et al. Hum Mol Genet. 2001 Sep;10:1889-900; Casey G et al. JAMA. 2005 Feb;293:799-809; Stojcev Z et al. Acta Biochim Pol. 2013 Jun;60:195-8), and based on an internal structural assessment, both of these variants are anticipated to result in a significant decrease in structural stability (Ambry internal data). This alteration has been classified as pathogenic using the following lines of evidence: in silico prediction models, segregation with disease, clinical phenotype including tumor characteristics, mutation co-occurrence, and functional studies (Thompson B et al. Hum Mutat. 2013 Jan;34(1):200-9; Thompson B et al. Nat Genet. 2014 Feb;46(2):107-15; available at [www.insight-group.org/variants/classifications/]). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation.
Color Diagnostics, LLC DBA Color Health	RCV000570680	SCV000684820	pathogenic	Hereditary cancer-predisposing syndrome	2023-04-07	criteria provided, single submitter	clinical testing	This missense variant replaces threonine with methionine at codon 117 of the MLH1 protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). Multiple functional studies have reported that this variant impacted in vitro mismatch repair activity (PMID: 11781295, 17135187, 17510385, 20020535, 23403630). This variant has been reported in over 20 individuals and families affected with Lynch syndrome (PMID: 8566964, 8574961, 9806477, 10349986, 10480359, 10732761, 11385712, 12362047, 12200596, 12373605, 12919140, 20233461, 15713769, 17026620, 18566915, 19419416, 19698169, 21404117, 22322191, 23403630) and has been reported to segregate with disease in multiple families (PMID: 22949379). This variant has been identified in 1/251388 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Loss of MLH1 function is a known mechanism of disease. Based on the available evidence, this variant is classified as Pathogenic.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp	RCV000075666	SCV000696163	pathogenic	Lynch syndrome	2016-04-15	criteria provided, single submitter	clinical testing	Variant summary: The c.350C>T variant in MLH1 gene is a missense change that alters a highly conserved nucleotide and 4/4 in silico tools predict deleterious outcome. The variant has been reported in multiple affected individuals and was shown to segregate with the disease (Wei_CG_2003). IHC showed selective loss of the MLH1 protein in tumors from patients testing positive for the variant of interest and cells containing the T117M lost the ability to repair mismatched DNA both in vivo and in vitro (Takanashi, 2007; Hinrichsen, 2016). The variant is absent from the large control population dataset of ExAC. Lastly, a reputable database/diagnostic center classified the variant of interest as Pathogenic. Taken together, the variant was classified as Pathogenic.
Quest Diagnostics Nichols Institute San Juan Capistrano	RCV000160518	SCV000888183	pathogenic	not provided	2019-09-12	criteria provided, single submitter	clinical testing	The MLH1 c.350C>T (p.Thr117Met) variant has been reported in the published literature in individuals affected with a Lynch syndrome associated cancer (PMIDs: 16451135 (2006), 28135145 (2017), 28449805 (2017), 28874130 (2017), 30521064 (2019)). Functional studies show that this variant shows significantly reduced MLH1 protein expression and DNA mismatch repair activity (PMIDs: 11781295 (2002), 17135187 (2006), 17510385 (2007), 23403630 (2013)). The frequency of this variant in the general population, 0.000004 (1/251388 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is consistent with pathogenicity. Based on the available information, this variant is classified as pathogenic.
Clinical Genetics and Genomics, Karolinska University Hospital	RCV000160518	SCV001449886	pathogenic	not provided	2017-04-13	criteria provided, single submitter	clinical testing
Revvity Omics, Revvity	RCV000160518	SCV002017497	pathogenic	not provided	2022-09-27	criteria provided, single submitter	clinical testing
Genetic Services Laboratory, University of Chicago	RCV000160518	SCV002069692	pathogenic	not provided	2021-04-05	criteria provided, single submitter	clinical testing
Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital	RCV000160518	SCV002552422	pathogenic	not provided	2024-02-06	criteria provided, single submitter	clinical testing
KCCC/NGS Laboratory, Kuwait Cancer Control Center	RCV003229801	SCV003927261	pathogenic	Colon cancer	2023-05-31	criteria provided, single submitter	clinical testing	is neutral and non-polar, at codon 117 of the MLH1 protein (p.Thrl 17Met). This variant is present in population databases (rs63750781, gnomAD 0.003%). This missense change has been observed in individual(s) with colon cancer and Lynch syndrome (PMID: 12112654, 15713769, 18566915, 19698169, 20233461, 22322191). ClinVar contains an entry for this variant (Variation ID: 17094). Experimental studies have shown that this missense change affects MLH1 function (PMID: 9697702, 11429708, 1178i295, 12810663, 17135187, 17510385, 23403630). This variant disrupts the p.Thrl 17 amino acid residue in MLH1. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 9697702, 11555625, 12810663). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. Pathogenic/likely pathogenic variants in the MLH1 gene are known to cause Hereditary Non-Polyposis Colorectal Cancer Syndrome, also known as Lynch Syndrome.
KCCC/NGS Laboratory, Kuwait Cancer Control Center	RCV000018626	SCV004015210	pathogenic	Colorectal cancer, hereditary nonpolyposis, type 2	2023-07-07	criteria provided, single submitter	clinical testing	This sequence change replaces threonine with methionine at codon 117 of the MLH1 protein (p.Thr117Met). This variant is not present in population databases (gnomAD). This variant has been observed in many families and individuals with colon cancer and Lynch syndrome (PMID: 18566915, 22322191, 20233461, 15713769, 12112654, 19698169). ClinVar contains an entry for this variant (Variation ID: 17094). Multiple experimental studies have shown that this missense change results in an unstable protein with disrupted protein interactions and defective mismatch repair activity (PMID: 11781295, 17135187, 23403630, 12810663, 11429708, 17510385, 9697702). A multifactorial likelihood analysis incorporating genetic, clinical, and bioinformatic data (PMID: 19267393), and an algorithm developed specifically for the MLH1 gene (PMID: 18383312), indicate that this variant has a high probability of being pathogenic. In addition, multiple missense mutations have been reported in this region in individuals with colorectal cancer, suggesting that this is an important domain for MLH1 function (PMID: 17510385). In-silico predictions show pathogenic computational verdict based on 11 pathogenic predictions from BayesDel_addAF, DANN, DEOGEN2, EIGEN, FATHMM-MKL, LIST-S2, M-CAP, MVP, MutationAssessor, MutationTaster and SIFT vs 1 benign prediction from PrimateAI and the threonine residue is highly conserved. Therefore, this sequence change has been classified as Pathogenic.
Baylor Genetics	RCV000018626	SCV004195040	pathogenic	Colorectal cancer, hereditary nonpolyposis, type 2	2023-10-20	criteria provided, single submitter	clinical testing
OMIM	RCV000018626	SCV000038909	pathogenic	Colorectal cancer, hereditary nonpolyposis, type 2	2003-09-01	no assertion criteria provided	literature only
Pathway Genomics	RCV000144599	SCV000189926	pathogenic	Lynch syndrome 1	2014-07-24	no assertion criteria provided	clinical testing
Department of Pathology and Laboratory Medicine, Sinai Health System	RCV001353627	SCV000592354	pathogenic	Endometrial carcinoma		no assertion criteria provided	clinical testing	The MLH1 p.Thr117Met variant was identified in the literature in at least 2 of 160 proband chromosomes from Lynch syndrome families, and has been characterized in several functional studies (Andersen 2012, Brieger 2002, Hinrichsen 2013, Jager 2001, Liu 1996, Perera 2010, Plotz 2006, Takahashi 2007, Trojan 2002, Vogelsang 2009), and was previously identified by our laboratory in 1 individual with colorectal cancer. The p.Thr117Met variant was also identified in dbSNP (ID: rs63750781) “With allele of Uncertain significance”, MutDB, HGMD, “Mismatch Repair Genes Variant Database”, “InSiGHT Colon Cancer Database”, “Zhejiang Colon Cancer Database”, “MMR Gene Unclassified Variants Database”, UMD (28X as a Causal variant), LOVD and was classified as pathogenic by InSiGHT and OMIM (submitted within the ClinVar database). The p.Thr117Met residue is conserved across mammals and lower organisms, and computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) suggest that the p.Thr117Met variant may impact the protein. A study by Perera (2010) found that the p.Thr117Met variant was associated with significantly unbalanced allelic expression, and tumour analysis of the positive proband showed MLH1-deficiency and high microsatellite instability, suggesting that this could be considered a deleterious mutation. Functional studies characterizing the variant demonstrated reduced mismatch repair activity and nuclear localization (Andersen_2012, Brieger 2002, Jager 2001, Trojan 2002, Takahashi 2007, Plotz 2006, Vogelsang 2009); some of these studies detected normal expression of MLH1 and interaction with PMS2, while other studies found a reduction in MLH1 expression and PMS2 interaction. Three studies have suggested that the p.Thr117Met missense mutation may inactivate mismatch repair (MMR) activity by altering the capacity of this mutant protein to bind and/or hydrolyze adenosine triphosphate (ATP) (Brieger 2002, Jager 2001, Drost 2009). In summary, based on the above information, this variant meets our laboratory’s criteria to be classified as pathogenic.
Mayo Clinic Laboratories, Mayo Clinic	RCV000160518	SCV000691846	pathogenic	not provided		no assertion criteria provided	clinical testing
Ding PR Lab, Sun Yat-sen University Cancer Center	RCV000144599	SCV001250869	likely pathogenic	Lynch syndrome 1		no assertion criteria provided	clinical testing
Constitutional Genetics Lab, Leon Berard Cancer Center	RCV001249927	SCV001423869	pathogenic	Lynch-like syndrome	2019-07-01	no assertion criteria provided	clinical testing
Clinical Genetics, Academic Medical Center	RCV000160518	SCV001923457	pathogenic	not provided		no assertion criteria provided	clinical testing
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+	RCV000160518	SCV001952426	pathogenic	not provided		no assertion criteria provided	clinical testing
Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center	RCV000160518	SCV001975615	pathogenic	not provided		no assertion criteria provided	clinical testing
CZECANCA consortium	RCV001353627	SCV003804336	pathogenic	Endometrial carcinoma	2023-02-21	no assertion criteria provided	clinical testing